Table 3 Combining EZH2 inhibitors with other chemotherapy agents in lymphoid malignancies
From: EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
Treatment regimen(s) | Malignancies | Authors |
|---|---|---|
GSK126 and Etoposide | GC-DLBCL, BL | Smonskey M., et al. [155] |
GSK126 and Pentoxifylline | MM, T-ALL | Neo WH., et al. [56] |
GSK126/EPZ-6438/DZnep and Panobinostat | MM, MCL | Kalushkova A., et al. [158]; Fiskus W., et al. [117]; Fiskus W., et al. [159]; Harding T., et al. [157] |
DZnep and JQ1 | BL, MCL, GC-DLBCL | Zhao X., et al. [51] |
DZnep and Daunoblastine | T-ALL | D’Angelo V., et al. [156] |
UNC1999 and Bortezomib/Carfilzomib | MM | Rizq O., et al. [154] |
DZnep and Vorinostat | MCL, BL | Zhang X., et al. [54] |
GSK126/Dznep and ACY-957/1044 | EZH2-mutant GC-DLBCL | Johnson DP., et al. [160] |